Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

Table 2 Correlation coefficients for the association of serum periostin and TNC levels with subject characteristics in asthmatic patients

	Periostin		TNC
	r_s	P value	r_s	P value
Sex (male)	− 0.033	0.711	− 0.025	0.780
Age (years)	0.261	0.003*	− 0.074	0.410
Age at asthma onset (years)	0.283	0.001*	− 0.019	0.831
Duration of asthma (years)	− 0.165	0.066	0.019	0.833
BMI (kg/m²)	− 0.071	0.428	0.029	0.749
Pack-year smoking history (pack year)	0.014	0.878	− 0.032	0.722
GINA step 4 + 5	− 0.224	0.012*	0.274	0.002*
AERD	0.119	0.186	0.132	0.142
Atopic dermatitis	− 0.016	0.857	0.003	0.969
Allergic rhinitis	− 0.041	0.651	− 0.027	0.763
Chronic sinusitis	0.088	0.329	0.026	0.771
Daily dose of ICS (FP equivalent dose, µg)	− 0.194	0.029*	0.206	0.020*
Daily dose of OCS (PSL equivalent dose, mg)	− 0.068	0.446	0.096	0.286
ACT score, n = 125	0.240	0.007*	− 0.108	0.232
FeNO (ppb)	0.319	< 0.001*	0.057	0.529
Peripheral neutrophils (cells/μL)	− 0.124	0.168	0.189	0.034*
Peripheral eosinophils (cells/μL)	0.360	< 0.001*	0.063	0.486
Serum IgE (IU/mL)	0.110	0.221	0.259	0.003*
Th2-high	0.195	0.029*	0.046	0.609
FVC (L)	− 0.167	0.061	− 0.056	0.536
%FVC (predicted, %)	− 0.047	0.604	− 0.104	0.246
FEV₁ (L)	− 0.167	0.061	− 0.099	0.271
%FEV₁ (predicted, %)	− 0.203	0.023*	− 0.042	0.642
FEV₁/FVC ratio (%)	− 0.084	0.349	− 0.149	0.096
PEF (L/s)	− 0.146	0.103	− 0.057	0.524
%PEF (predicted, %)	− 0.024	0.786	− 0.103	0.252
MMF (L)	− 0.250	0.005*	− 0.058	0.522
%MMF (predicted, %)	− 0.195	0.028*	− 0.140	0.118

ACT asthma control test, AERD aspirin-exacerbated respiratory disease, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, IgE immunoglobulin E, MMF mid-maximal flow rate, OCS oral corticosteroids, PEF peak expiratory flow, PSL prednisolone, Th2 T-helper cell type 2, TNC tenascin-C
*P < 0.05

ISSN: 1710-1492